Eli Lilly stock (US5324571083): Q1 revenue surge 56% on obesity drug boom

Eli Lilly reported first-quarter 2026 revenues of $19.8 billion, up 56% year-over-year, driven by blockbuster obesity and diabetes treatments Mounjaro and Zepbound. The stock retreated 2.72% after an initial post-earnings rally.

Eli Lilly delivered a standout first-quarter 2026 performance, posting revenues of $19.8 billion, a 56% increase year-over-year, according to MarketBeat as of April 30, 2026. Earnings per share reached $8.55, beating consensus estimates of $6.97 by $1.58. The pharmaceutical giant's strong results were fueled by surging demand for its obesity and diabetes franchises, particularly Mounjaro and Zepbound, which have become central to the company's growth trajectory in the high-demand GLP-1 therapy market.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eli Lilly and Company
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: United States (Indianapolis, Indiana)
• Core markets: Global pharmaceutical markets, obesity and diabetes treatments
• Key revenue drivers: Mounjaro (tirzepatide), Zepbound, GLP-1 therapies
• Home exchange/listing venue: NYSE (ticker: LLY)
• Trading currency: USD

Eli Lilly: core business model

Eli Lilly operates as a diversified pharmaceutical company focused on research, development, manufacturing, and marketing of prescription medications across multiple therapeutic areas. The company's portfolio spans oncology, immunology, cardiovascular disease, endocrinology, and neuroscience. In recent quarters, the company has pivoted significant resources toward obesity and diabetes treatments, capitalizing on the explosive demand for GLP-1 receptor agonists. This strategic focus reflects broader market trends and positions Eli Lilly as a key player in one of the fastest-growing pharmaceutical segments globally.

Main revenue and product drivers for Eli Lilly

Mounjaro generated $8.66 billion in Q1 2026 sales, representing a 125% year-over-year increase, according to ad-hoc-news as of May 2026. Zepbound, the obesity indication of tirzepatide, contributed $4.16 billion in quarterly revenue, up 80% year-over-year. These two products alone accounted for a substantial portion of the company's total revenue growth, reflecting sustained US demand for obesity treatments amid rising prevalence rates and expanding insurance coverage. The company's ability to scale manufacturing and supply these blockbuster drugs has become a critical competitive advantage in the GLP-1 market.

The stock traded at $948.45 USD on May 8, 2026, on the NYSE, down 2.72% from prior levels following a post-earnings pullback, according to MarketBeat as of May 8, 2026. The retreat came after shares surged approximately 13% in the week following the earnings announcement, indicating profit-taking by investors after the initial enthusiasm over the beat.

Guidance and capital expansion

Eli Lilly raised its full-year 2026 earnings guidance to $35.50–$37.00 per share, compared to consensus estimates of $34.39, and provided revenue guidance of $82.0–$85.0 billion, above the consensus estimate of $81.9 billion, according to MarketBeat as of April 30, 2026. On May 11, 2026, the company announced an additional $4.5 billion capital investment across two Indiana manufacturing sites, bringing total Indiana capital expansion commitments since 2020 to more than $21 billion. This substantial reinvestment underscores management confidence in sustained demand for its obesity and diabetes franchises and reflects the company's commitment to expanding production capacity to meet global market needs.

Conclusion

Eli Lilly's Q1 2026 results demonstrate the company's dominant position in the high-growth obesity and diabetes treatment market. With revenue growth of 56% driven by Mounjaro and Zepbound, combined with raised full-year guidance and significant capital investments in manufacturing capacity, the company has signaled confidence in sustained demand for GLP-1 therapies. While the stock retreated after initial post-earnings gains, the underlying fundamentals reflect robust market dynamics and operational execution that remain relevant for US investors tracking pharmaceutical sector performance and the evolving obesity treatment landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.